The prevalence of AD is drastically elevating in the aging society with the lack of
early diagnosis and therapy. Diagnosis is now based on the measurement of certain protein
aggregates in the brain together with memory tests and in some cases with imaging
methods, like CT. In this study, peripheral blood (plasma) and cerebrospinal fluid (CSF) will be
analysed by cutting-edge biochemical and computational methods.
Patient involvement:
Early AD, prodromal AD patients with age and gender matched
controls will be enrolled in three study sites (Sweden, Spain and Turkey). After signing
consent, peripheral blood and cerebrospinal fluid (CSF) will be collected and analysed. Please
note that the study is completely anonimized and involved individuals will not have any
benefits after participating in the study.
Workflow
Human and animal experiments will be carried out in parallel. In mouse models of
poor glymphatic clearance and Alzheimer’s disease, we will examine the metabolite profile
by using mass spectrometry. Data will be compared with human databases, thus, a more
focused metabolomics and glyconomics analysis will be carried out on human samples.
Differences between controls, prodromal and early AD patients will be characterized by
bioinformatics methods. The potential beneficial effects of selected metabolites will be
verified in cell culture assays. On the other hand, the druggability potential of some selected
proteins will also be tested, providing a solid preclinical proof-of-concept for further clinical
applications.